Decision On Moderna’s COVID-19 Vaccine For Adolescents Delayed – What You Need To Know
The FDA is delaying its decision to authorize Moderna Inc’s (NASDAQ:MRNA) COVID-19 vaccine for adolescents to assess the risk of…
Why Moderna Shares Are Rebounding From Friday’s Losses
Moderna, Inc. (NASDAQ: MRNA) shares have followed a downtrend ever since completing a double top formation in late September. After bottoming in early October, the stock reversed course and moved higher in anticipation of authorization for its COVID-19 booster shot.
Earnings Season Continues with State Street, Albertsons, and Sandvik Announcing on Monday Morning
Stocks appear to be pausing as rates start to rise. Before the U.S. markets opened, short-term U.S. Treasury yields were rising. The five-year yields rose to their highest levels in 20 months per Reuters.
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings.
The Daily Biotech Pulse: Moderna’s Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Piper Sandler Upgrades Moderna to Overweight
Piper Sandler analyst Edward Tenthoff upgrades Moderna (NASDAQ:MRNA) from Neutral to Overweight.